Gene · 10419
Papers3,714
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,714
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| PRMT5 Promotes Pancreatic Cancer Tumorigenesis via Positive PRMT5/C-Myc Feedback Loop. | MedComm (2020) | 2025 | 40384988 | PubTator, text mining | PubMed |
| MTA-cooperative PRMT5 inhibitors from cofactor-directed DNA-encoded library screens. | Proc Natl Acad Sci U S A | 2025 | 40377999 | PubTator, text mining | PubMed |
| Histone modifications and metabolic reprogramming in tumor-associated macrophages: a potential target of tumor immunotherapy. | Front Immunol | 2025 | 40375990 | PubTator, text mining | PubMed |
| Virtual High-Throughput Screening of Ligands for Disrupting PRMT5/pICLn Interaction in Prostate Cancer Cells. | ACS Med Chem Lett | 2025 | 40365403 | PubTator, text mining | PubMed |
| Molecular Mechanisms of Tumor Progression and Novel Therapeutic and Diagnostic Strategies in Mesothelioma. | Int J Mol Sci | 2025 | 40362535 | PubTator, text mining | PubMed |
| Mechanistic insights into CLNS1A-mediated chemoresistance and tumor progression in non-small cell lung cancer. | Cancer Lett | 2025 | 40345428 | PubTator, text mining | PubMed |
| PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti-TIGIT Therapy in Microsatellite-Stable Colorectal Cancer. | Adv Sci (Weinh) | 2025 | 40344511 | PubTator, text mining | PubMed |
| Splicing regulatory dynamics for precision analysis and treatment of heterogeneous leukemias. | Sci Transl Med | 2025 | 40333990 | PubTator, text mining | PubMed |
| miR-205-3p inhibits porphyromonas gingivalis lipopolysaccharide-induced human umbilical vein endothelial cells inflammation and apoptosis by targeting PRMT5. | Arch Oral Biol | 2025 | 40319839 | PubTator, text mining | PubMed |
| PRMT5 promotes full-length HTT expression by repressing multiple proximal intronic polyadenylation sites. | Nucleic Acids Res | 2025 | 40304179 | PubTator, text mining | PubMed |
| NELFCD Promotes Colon Cancer Progression by Regulating the DUSP2-p38 Axis. | Front Biosci (Landmark Ed) | 2025 | 40302325 | PubTator, text mining | PubMed |
| The E3 Ligase NEDD4L Prevents Colorectal Cancer Liver Metastasis via Degradation of PRMT5 to Inhibit the AKT/mTOR Signaling Pathway. | Adv Sci (Weinh) | 2025 | 40279519 | PubTator, text mining | PubMed |
| The expression of PRMT5 is associated with postoperative chemotherapeutic outcome in colon cancer. | BMC Cancer | 2025 | 40269778 | PubTator, text mining | PubMed |
| Semaphorin 6A phase separation sustains a histone lactylation-dependent lactate buildup in pathological angiogenesis. | Proc Natl Acad Sci U S A | 2025 | 40244673 | PubTator, text mining | PubMed |
| Discovery of a Potent and Selective Protein Arginine Methyltransferase 5 (PRMT5) PROTAC Degrader. | J Med Chem | 2025 | 40232306 | PubTator, text mining | PubMed |
| RNF187 Facilitates Proliferation and Migration of Human Spermatogonial Stem Cells Through WDR77 Polyubiquitination. | Cell Prolif | 2025 | 40197797 | PubTator, text mining | PubMed |
| PRMT5 deficiency in myeloid cells reprograms macrophages to enhance antitumor immunity and synergizes with anti-PD-L1 therapy. | J Immunother Cancer | 2025 | 40187753 | PubTator, text mining | PubMed |
| PRMT5-mediated methylation of METTL3 promotes cisplatin resistance in ovarian cancer by facilitating DNA repair mechanisms. | Cell Rep | 2025 | 40158218 | PubTator, text mining | PubMed |
| PRMT5 inhibitors: Therapeutic potential in pancreatic cancer. | Transl Oncol | 2025 | 40157258 | PubTator, text mining | PubMed |
| Alternative splicing: A key regulator in T cell response and cancer immunotherapy. | Pharmacol Res | 2025 | 40147681 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/10419/papers?page=16